Ana Liani Beisl Oliveira

ORCID: 0000-0002-6413-5727
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Public Health in Brazil
  • Biosimilars and Bioanalytical Methods
  • Global Public Health Policies and Epidemiology
  • Health, Nursing, Elderly Care
  • Biotechnology and Related Fields
  • Immunodeficiency and Autoimmune Disorders
  • Tuberculosis Research and Epidemiology
  • Healthcare during COVID-19 Pandemic
  • Pharmaceutical Economics and Policy

Fundação Oswaldo Cruz
2021-2023

Escola Nacional de Saúde Pública
2021

The 16th National Health Conference illustrated the interest of health councils to intervene in public policies order guarantee right technologies. INTEGRA project (Integration for Surveillance, Pharmaceutical Care, Science, Technology, and Innovation Health) is a partnership among Council, School Pharmacists, Oswaldo Cruz Foundation (Fiocruz), with support from Pan American Organization (PAHO), goal strengthening participation social engagement theme, as well integration practices within...

10.1590/1413-812320212611.18212021 article PT Ciência & Saúde Coletiva 2021-11-01

This study analyzes supply characteristics and factors associated with the treatment of rheumatoid arthritis in Brazil, a focus on disease course-modifying biological drugs (bioDMARDs). A retrospective was conducted secondary data from Outpatient Information System Unified Health System. Patients aged 16 years or older who were treated 2019 eligible. The analyses performed exposure relation to outcomes: bioDMARD use population size. included 155,679 patients, 84.6% whom women. There greater...

10.1590/1413-81232023285.13482022 article PT Ciência & Saúde Coletiva 2023-05-01

Abstract This study analyzes supply characteristics and factors associated with the treatment of rheumatoid arthritis in Brazil, a focus on disease course-modifying biological drugs (bioDMARDs). A retrospective was conducted secondary data from Outpatient Information System Unified Health System. Patients aged 16 years or older who were treated 2019 eligible. The analyses performed exposure relation to outcomes: bioDMARD use population size. included 155,679 patients, 84.6% whom women. There...

10.1590/1413-81232023285.13482022en article EN Ciência & Saúde Coletiva 2023-05-01
Coming Soon ...